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Phosphorylated forms of microtubule-associated protein tau accumulate in neuroﬁbrillary tangles in
Alzheimer’s disease. To investigate the effects of speciﬁc phosphorylated tau residues on its function,
wild type or phosphomutant tau was expressed in cells. Elevated tau phosphorylation decreased its
microtubule binding and bundling, and increased the number of motile tau particles, without affecting
axonal transport kinetics. In contrast, reducing tau phosphorylation enhanced the amount of tau bound
to microtubules and inhibited axonal transport of tau. To determine whether differential tau clearance is
responsible for the increase in phosphomimic tau, we inhibited autophagy in neurons which resulted in
a 3-fold accumulation of phosphomimic tau compared with wild type tau, and endogenous tau was
unaffected. In autophagy-deﬁcient mouse embryonic ﬁbroblasts, but not in neurons, proteasomal
degradation of phosphomutant tau was also reduced compared with wild type tau. Therefore, autophagic
and proteasomal pathways are involved in tau degradation, with autophagy appearing to be the primary
route for clearing phosphorylated tau in neurons. Defective autophagy might contribute to the accu-
mulaton of tau in neurodegenerative diseases.
 2013 Elsevier Inc. Open access under CC BY license.1. Introduction
The microtubule-associated protein tau is a cytoskeletal protein
expressed primarily in the central nervous systemwhere it stabilizes
microtubules and regulates neurite outgrowth. Several neurode-
generative diseases, collectively termed tauopathies, are character-
ized by intraneuronal inclusions of straight or paired helical
ﬁlaments of insoluble, highly phosphorylated tau (Ballatore et al.,
2007; Gallo et al., 2007). Interaction of tau with microtubules
occurs primarily through the repeatedmicrotubule-binding domains
located in the C-terminal half of tau. The inclusion of either 3 or 4
binding repeats is regulated by alternative splicing of exon 10, which
gives rise to either 3R or 4R tau isoforms (Goedert et al., 1989). Tau
also interacts with components of the plasmamembrane through its
amino terminal projection domain (Brandt et al., 1995; Gauthier-
Kemper et al., 2011; Pooler et al., 2012). Phosphorylation of tau
decreases its capacity to bind to and stabilize microtubules
(Bramblett et al., 1993; Busciglio et al., 1995), and recently we haveience (P037), King’s College
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 license.found that association of tau with the plasma membrane is also
regulated by phosphorylation (Pooler et al., 2012).
In Alzheimer’s disease, tau is highly phosphorylated, and many
of the tau phosphorylation sites targeted by glycogen synthase
kinase-3 (GSK-3), the primary candidate kinase for tau phosphor-
ylation, are also phosphorylated in insoluble tau isolated from
Alzheimer brain (Avila et al., 2012; Hanger et al., 2007, 2009).
Changes in protein phosphorylation have been reported to affect
axonal transport in models of neurodegenerative diseases. For
example, increased phosphorylation of neuroﬁlaments and the
microtubule-binding protein, MAP1B, reduces their respective rates
of axonal transport (Ackerley et al., 2003; Ma et al., 2000). In
contrast, elevated phosphorylation of tau results in an increased
overall slow rate of tau transport in neurons, and inhibiting GSK-3
phosphorylation of tau reduces its motility (Cuchillo-Ibanez et al.,
2008). Defective axonal transport has been suggested to underlie
some forms of neurodegenerative disease (De Vos et al., 2008;
Falzone et al., 2010), although the mechanisms responsible are not
established.
Because, in addition to affecting its transport, tau phosphorylation
affects its ability to be degraded (Ding et al., 2006; Johnson, 2006),we
examined the contributions of the ubiquitin-proteasome system
(UPS) and of macroautophagy (autophagy) to tau degradation in the
context of tau transport. Though the UPS eliminates short-lived
proteins that are targeted for degradation by the addition of
ubiquitin, the autophagic system removes long-lived, structural
T. Rodríguez-Martín et al. / Neurobiology of Aging 34 (2013) 2146e2157 2147proteins and/or damaged or misfolded proteins (Martinez-Vicente
and Cuervo, 2007; Shacka et al., 2008). Furthermore, a particular
form of autophagy, termed aggrephagy, eliminates accumulated and
aggregated ubiquitinated proteins, such as those deposited in the
brain in the tauopathies and therefore, this process is gaining
particular interest in neurodegenerative disease (Yamamoto and
Simonsen, 2011). Dysfunction of autophagy and the UPS in neurons
has been linked to a number of neurodegenerative disorders charac-
terized by accumulation of misfolded protein aggregates (Bauereis
et al., 2011; de Vrij et al., 2004; Li et al., 2010; Martinez-Vicente and
Cuervo, 2007; Riederer et al., 2011; Tai and Schuman, 2008). Tau
degradation by each of these processes has been the subject of
extensive research. However, though some studies suggest that tau is
not a substrate of the proteasome (Brown et al., 2005; Delobel et al.,
2005; Feuillette et al., 2005), others have reported that inhibition of
the UPS results in tau accumulation in cells (David et al., 2002; Liu
et al., 2009; Zhang et al., 2005). Autophagy has also been shown to
degrade wild type and modiﬁed forms of tau, including caspase-
cleaved and C-terminally truncated species (Dolan and Johnson,
2010; Wang et al., 2010). However, induction of autophagy with
rapamycin in adult rat brain does not result in proteolysis of endog-
enous tau, suggesting that this lysosomal system might not partici-
pate in physiological tau degradation (Zhang et al., 2009).
In this study, we have used mutant forms of tau, which mimic
permanent states of phosphorylation and dephosphorylation, to
investigate tau function. In particular, we have examined the effect
of tau phosphorylation on its rate of axonal transport and its
degradation by the UPS and autophagy. We show here that phos-
phomimic tau binds less to microtubules and exhibits an increased
number of motile tau particles in axons compared with wild type
tau. We also show that, in primary cortical neurons, exogenously
expressed phosphomimic and wild type tau are targets for auto-
phagy, and endogenous tau is not. In the absence of autophagy,
degradation of tau by the UPS in neurons is minimal.
2. Methods
2.1. Plasmids
Plasmids expressing the longest human central nervous system
tau isoform (2N4R; WTtau) and 2 tau phosphomimic mutants,
E18tau and E27tau, with 18 or 27 serine/threonine residues
mutated to glutamate, respectively, were gifts from M. Goedert
(MRC Laboratory of Molecular Biology, Cambridge, UK). The tau
sequences were cloned into the enhanced green ﬂuorescent protein
(EGFP)-C1 vector (BD Biosciences, Clontech) to generate a construct
inwhich EGFPwas fused to the amino terminus of tau. Site-directed
mutagenesis (Quikchange kit, Stratagene) was used to create an
additional EGFP-tagged tau mutant construct encoding A18tau in
which the same 18 serine/threonine residues that were mutated in
E18tau were substituted by alanine (Cuchillo-Ibanez et al., 2008).
Thus, A18tau represented a mimic of permanent dephosphoryla-
tion at these sites in tau because it cannot be phosphorylated at
these 18 residues. The E27tau sequence was also cloned into the
DsRed ﬂuorescent protein vector (BD Biosciences, Clontech). The
plasmid expressing microtubule-associated protein 1 light-chain 3
(LC3), fused to EGFP, was a gift from A.M. Tolkovsky (University of
Cambridge, UK).
2.2. Cell culture and transfection
Embryonic day 18 (E18) rat cortical neurons were cultured in
Neurobasal medium (Life Technologies, Inc), supplemented with
B27 (Invitrogen), as described previously (Cuchillo-Ibanez et al.,
2008). Chinese hamster ovary (CHO) cells were cultured in Ham’sF12 and mouse embryonic ﬁbroblasts (MEFs) in Dulbecco’s Modi-
ﬁed Eagle’s Medium, each containing 10% (vol/vol) fetal calf serum.
All culture mediawere supplemented with 100 U/mL penicillin, 100
mg/mL streptomycin, and 2 mM L-glutamine. Cortical neurons were
transfected using either calcium phosphate (Promega) for live
microscopy or Lipofectamine 2000 (Invitrogen) for analysis of cell
lysates. CHO cells and MEFs were transfected using Lipofectamine
(Invitrogen), following the manufacturers’ instructions.
2.3. Time-lapse imaging of transfected neurons
E18 rat cortical neurons (5 days in vitro [DIV]) were transfected
with plasmids expressing WTtau, E18tau, E27tau or A18tau, and
time-lapse images were recorded after 48 hours. Coverslips were
placed in a sealed chamber with Neurobasal medium containing
B27 and maintained at 37 C with 5% CO2 perfusion on the stage of
an Axiovert 200M Zeiss microscope. Epiﬂuorescence illumination
was attenuated to 8% using neutral density ﬁlters. Images were
collected at 1e2-second intervals for 2e4 minutes using a Plan-
ApoChromat 100 1.4 NA oil immersion objective (1 pixel ¼
0.063 mm), a green ﬂuorescent protein ﬁlter set and an AxioCam
MRm camera. Movement of ﬂuorescent particles was analyzed
using AxioVision software 4.6.3 (tracking module). Fluorescent
particles that moved <0.3 mm between consecutive frames were
considered to be pausing (typically corresponding to a rate of <0.2
mm/s). Statistical analyses were performed using a 2-tailed Student
t test.
2.4. Immunocytochemistry and ﬂuorescence microscopy
Transfected CHO and MEF cells were ﬁxed in 4% (wt/vol) para-
formaldehyde 24 hours after transfection. All incubations were
carried out at room temperature. Cells were blocked using 1% (wt/
vol) Triton X-100, 10% (vt/vol) fetal calf serum in phosphate buff-
ered saline (PBS) for 20 minutes, and then stained for a-tubulin
(mouse monoclonal, DM1A, Invitrogen) for 1 hour. The anti-mouse
Texas Red-coupled secondary antibody was added for 1 hour in the
dark. Nuclear staining was performed using Hoescht 33342 (5 mg/
mL bisbenzimide in PBS). Fluorescence microscopy was performed
using an Axioskop microscope (Zeiss), equipped with a camera
(CoolSnap HQ, Photometrics) and with Plan-NeoFluor 20 0.50 NA,
40 0.75 NA, and 100 1.30 NA objectives.
2.5. Gel electrophoresis and Western blot analyses
For protein analysis, 6-well plates containing 1  106 neurons
per well, were rinsed with PBS at 4 C and cells were scraped into
hot (2) Laemmli sample buffer. Proteins were separated on 10%
(wt/vol) sodium dodecyl sulfate (SDS)-polyacrylamide gels and
transferred to nitrocellulose membranes. Membranes were probed
with antibodies to tau (rabbit polyclonal, DAKO or TP70), b-actin
(mouse monoclonal, clone AC15, Sigma), S6 (mouse monoclonal,
clone 54D2, Cell Signaling Technology) or P-S6 (mouse monoclonal,
clone 2F9, Cell Signaling Technology). For LC3 analysis, proteins
were separated on 15% (wt/vol) gels and blots were probed with
LC3 antibody (rabbit polyclonal, Sigma). Antigens were visualized
using secondary antibodies coupled to infra-red dyes and an
Odyssey scanner (Li-Cor Biosciences).
2.6. Microtubule binding assay
Assays for microtubule binding of tau were performed as
described previously (Ding et al., 2006), with somemodiﬁcations.
Brieﬂy, CHO cells were transfected for 24 hours with plasmids
expressing EGFP-tagged WTtau, E18tau, E27tau, or A18tau. Cells
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fer (80 mM piperazine-N,N0bis-2-ethanesulfonic acid, pH 6.8, 1
mM guanosine-50-triphosphate, 1 mM MgCl2, 1 mM ethylene
glycol-bis(2-aminoethyl)-N,N,N0,N0-tetraacetic acid, 0.5% (wt/
vol) Triton X-100 and 30% (vol/vol) glycerol), containing 1 mM
phenylmethylsulfonylﬂuoride, Complete protease inhibitor
(Roche), 0.5 mM okadaic acid (Calbiochem), and 10 mM taxol
(Sigma). Cell suspensions were centrifuged at 5000g for 10
minutes at room temperature and an aliquot of the supernatant
was retained as the postnuclear lysate (input). The remaining
postnuclear lysate was centrifuged at 100,000g for 1 hour at
room temperature. The supernatant (unbound) was retained and
the pellet (microtubule-bound) was rinsed twice and resus-
pended in PIPES buffer. The proteins in each fraction were
separated on 10% (wt/vol) SDS-polyacrylamide gels and blots
were probed with the tau polyclonal antibody (DAKO).
2.7. Immunoprecipitation
Rat cortical neurons (5 DIV) were transfected with constructs
expressing EGFP-tagged WTtau or phosphomutant tau. After 48
hours, neurons were lysed and EGFP-tau was immunoprecipitated
using an agarose-conjugated polyclonal antibody to GFP (Santa
Cruz Biotechnology, Inc), as described previously (Cuchillo-Ibanez
et al., 2008). Immunoprecipitated proteins were probed on
Western blots, using antibodies recognizing kinesin heavy chain
(MAB1614, Chemicon) and tau (DAKO).
2.8. Glutathione-S-transferase binding assay
Puriﬁed recombinant WTtau and E27tau proteins were
prepared as described (Utton et al., 1997). Glutathione-S-
transferase (GST) fusion proteins were prepared and GST binding
was assayed as described previously (Usardi et al., 2011). An equi-
molar amount of puriﬁed GST-kinesin light chain 1 or 2, bound to
glutathione Sepharose 4B beads, was incubated with puriﬁed
recombinant human tau in modiﬁed RIPA buffer (20 mM Tris-HCl,
pH 7.4, containing 150 mM sodium chloride, 10 mM sodium
ﬂuoride, 1 mM sodium orthovanadate, 1 mM ethylenediamine-
tetraacetic acid, 1 mM ethylene glycol-bis(2-aminoethyl)-N,N,N0,
N0-tetraacetic acid, 0.2 mM phenylmethylsulfonyl ﬂuoride, 1% [vol/
vol] Nonidet 40, Complete protease inhibitor [Roche]) for 1 hour at
4 C with rotation. The GST-Sepharose beads were pelleted at 500g
for 1 minute at 4 C, washed 3 times with modiﬁed RIPA buffer, and
resuspended in Laemmli sample buffer containing 40 mM dithio-
threitol. GST-bound proteins were analyzed on Western blots pro-
bed with an antibody to total tau (TP70) (Davis et al., 1995).Fig. 1. Tau phosphomutants. The diagram shows the positions in the longest human tau
glutamate (to mimic phosphorylation) in E18tau and E27tau, or to alanine (to preclude pho
(MT)-binding domain.3. Results
3.1. Tau phosphomutants exhibit differential microtubule binding in
cells
We ﬁrst analyzed the interaction of wild type and phospho-
mutant tau with microtubules. Tau constructs included: (1) the
longest human central nervous system tau isoform (WTtau, 441
residues); (2) mutant E18tau, in which serine or threonine residues
are mutated to glutamate at 18 sites to mimic a permanent state of
phosphorylation; (3) mutant E27tau, with 27 serine and threonine
sites mutated to glutamate; or (4) A18tau, inwhich alanine replaces
serine or threonine to preclude phosphorylation at these sites
(Cuchillo-Ibanez et al., 2008) (Fig. 1).
To assess the microtubule bundling properties of each of the tau
constructs used, CHO cells were transiently transfected with plas-
mids expressing each tau species fused to the C-terminus of EGFP
(Fig. 2A). Microtubules in tau-transfected CHO cells were visualized
using an antibody to a-tubulin. Twenty-four hours after trans-
fection, cells expressing WTtau displayed widespread microtubule
bundling (Fig. 2A, WTtau, arrows) with rings of tubulin apparent at
the cell periphery. Cells expressing WTtau were characteristically
smaller and more rounded than untransfected CHO cells. Expres-
sion of either E18tau or E27tau, the mimics of permanent phos-
phorylation, resulted in a dramatic reduction in microtubule
bundling compared with WTtau expression in CHO cells (Fig. 2A,
E18tau and E27tau). Even in highly expressing cells, microtubule
bundling was rarely observed with the tau phosphomimics, and the
cellular morphology was similar to that of untransfected CHO cells.
In contrast, expression of the nonphosphorylatable tau mutant,
A18tau, resulted in a marked increase in microtubule bundling in
CHO cells, compared with WTtau (Fig. 2A, A18tau, arrows). Cells
exhibiting very low amounts of A18tau also contained abundant
microtubule bundles (Fig. 2A, asterisks). Similar to cells expressing
WTtau, A18tau expression also resulted in cells with a smaller and
more rounded morphology than their untransfected counterparts.
Themicrotubule bundling abilities of the tau phosphomutants were
quantiﬁed and expressed as the percentage of tau-expressing cells
containing microtubule bundles (Fig. 2B). In cells expressing low
amounts of tau, we found signiﬁcant differences in the behaviors of
the different phospho-tau mutants compared with WTtau (Fig. 2B;
t test, p < 0.01). Low expression of A18tau resulted in bundled
microtubules in 84% of the cells, compared with only 26% of the
cells containing bundles with WTtau. Low expression of either of
the 2 phosphomimic taumutants resulted in negligiblemicrotubule
bundling (Fig. 2B, left). In cells expressing high amounts of tau,
A18tau bundled microtubules in 92% of the cells, which was similarisoform (2N4R, 441 residues) of the serine (S) or threonine (T) residues mutated to
sphorylation) in A18tau. R1, R2, R3, and R4 are the repeat regions of the microtubule
Fig. 2. Microtubule bundling of tau constructs. (A) CHO cells were transfected with WTtau, E18tau, E27tau, or A18tau and tau expression was visualized by EGFP ﬂuorescence.
Microtubules were labeled using the monoclonal a-tubulin antibody, DM1A. WTtau and A18tau exhibited a greater ability to bundle microtubules (arrows). Asterisks indicate cells
with microtubule bundles in the presence of low amounts of A18tau. Scale bar, 50mm. (B) Quantiﬁcation of microtubule-bundling in cells expressing high or low amounts of tau.
Values shown are mean  standard error of the mean. ** p < 0.01; *** p < 0.001, Student t test, relative to WTtau. Abbreviations: CHO, Chinese hamster ovary; EGFP, enhanced green
ﬂuorescent protein; MT, microtubule.
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18% and 9% of the cells, respectively. These results agree with
previous ﬁndings that overexpression of wild type tau increases its
binding to microtubules and induces microtubule bundling, and
that these effects are reversed by increased phosphorylation (Kanai
et al., 1989; Wagner et al., 1996).
The most likely explanation for the changes in microtubule
bundling that we observed is differential tubulin binding of the
phosphomutant tau species. Therefore, to quantify the microtubule
binding properties of different tau forms, CHO cells were transfected
with constructs expressing WTtau, E18tau, E27tau, or A18tau. Forty-
eight hours after transfection cells were lysed and fractionated into
microtubule-bound and unbound components, based on their dif-
ferential solubility (Ding et al., 2006). Comparative analysis of the cell
lysates onWestern blots shows that each of the tau mutants exhibits
a distinct migration pattern, with E18tau and E27tau exhibiting the
slowest, and A18tau the fastest, mobility on SDS-polyacrylamide gelelectrophoresis (Fig. 3A). The amount of tau bound to microtubules,
as a proportion of unbound tau, was expressed relative to WTtau in
the transfected CHO cells (Fig. 3B). The results show that E27tau has
a signiﬁcantly impaired ability to bind to microtubules compared
with WTtau (approximately 50%; p < 0.05), in agreement with
earlier in vitro ﬁndings (Smith et al., 2000). E18tau also showed
a trend for reduced microtubule binding of approximately 30%, but
this difference was not statistically signiﬁcant. In contrast, A18tau
exhibited an increase of approximately 70% in its ability to bind
microtubules, compared with WTtau (Student t test, p < 0.05). The
results support previous ﬁndings that binding of tau to microtubules
is dependent on the phosphorylation state of tau (Bramblett et al.,
1993; Busciglio et al., 1995). Thus E18tau and E27tau both appear
to act as functional mimics of phosphorylated tau, and A18tau as
a mimic of dephosphorylated tau, with respect to binding to and
bundling of microtubules (Eidenmuller et al., 2001; Leger et al., 1997;
Smith et al., 2000).
Fig. 3. Microtubule binding of wild type and phosphomutant tau. (A) CHO cells
transfected with A18tau, WTtau, E18tau, and E27tau were separated into microtubule-
bound and unbound fractions and analyzed using Western blot using an antibody to
tau (DAKO). (B) Quantiﬁcation of microtubule-bound/unbound expressed relative to
WTtau (mean  standard error of the mean; n ¼ 3); * p < 0.05, Student t test, relative
to WTtau. (C) Coexpression of DsRed-tagged WTtau and EGFP-tagged E27tau in rat
cortical neurons. Arrows indicate colocalization of WTtau and E27tau and asterisks
indicate individual E27tau particles. Scale bar, 10 mm. Abbreviations: CHO, Chinese
hamster ovary; EGFP, enhanced green ﬂuorescent protein; MT, microtubule.
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differential localization, we cotransfected rat primary cortical
neurons with plasmids encoding WTtau fused to DsRed, together
with EGFP-tagged E27tau. In axons of cotransfected neurons,
WTtau and E27tau were widely distributed as diffuse segments
and as bright puncta (Fig. 3C). Interestingly, although manyWTtau
puncta colocalized with E27tau (Fig. 3C, arrows), several E27tau
puncta appeared to be WTtau-negative (Fig. 3C, asterisks). The
reason for the apparent lack of colocalization of E27tau with
WTtau throughout the axon is not clear, although it is possible that
this could be because of differential microtubule binding of the 2
tau species.3.2. Permanent phosphorylation does not affect the kinetic
parameters of tau fast axonal transport
In previous studies of tau transport in neurons, we reported that
axonal motility of tau is a microtubule-dependent process (Utton
et al., 2005) and that E18tau and E27tau exhibited signiﬁcantly
increased overall rates of slow axonal transport, whereas A18tau
moved more slowly than WTtau (Cuchillo-Ibanez et al., 2008). To
investigate the mechanism underlying the altered rates of transport
exhibited by the phosphotau mutants, we acquired time-lapse
movies of individual wild type and mutant tau particles in rat
cortical neurons (Fig. 4A and Supplementary Videos 1e3). The rates
of fast axonal transport of each form of tau were calculated,
excluding periods during which the tau particles were paused.
Interestingly, no motile particles of A18tau were observed during
any of the recordings made after expression in neurons and, hence,
a kinetic analysis of the axonal transport of A18tauwas not possible.
This lack of motility might be because of the increased microtubule
binding of A18tau (Fig. 3B) and hence this is a likely contributing
factor to the reduced rate of overall slow transport of A18tau that
we reported previously (Cuchillo-Ibanez et al., 2008).
Kinetic analysis of all moving tau particles was used to deter-
mine their rates of transport between pauses, time spent pausing,
number of pauses, and longest distance traveled by each particle
during the recording period (Fig. 4B). The rates of fast axonal
transport of WTtau, E18tau, and E27tau were determined to be
0.33e0.41 mm/s, in line with our previous report of 0.36 mm/s for
kinesin-driven transport of the human 0N4R tau isoform (Utton
et al., 2005). Similar rates have been obtained for moving parti-
cles of recombinant kinesin (0.37 mm/s) (Thorn et al., 2000) and
neuroﬁlaments (0.40 mm/s) (Wang et al., 2000), consistent with
kinesin-driven fast axonal transport. We could not detect any
statistically signiﬁcant difference between the rate of transport of
WTtau and either of the 2 phosphomimic tau species. Comparison
of the time spent pausing, the number of pauses, and the longest
distance traveled byWTtau and phosphomimic tau also revealed no
differences in these parameters. Our results indicate that alter-
ations in tau that mimic a permanent state of phosphorylation do
not affect the kinetic parameters of fast axonal transport, based on
a study of individual tau particles. However, the complete lack of
mobility of particles containing A18tau, suggests that lack of
phosphorylation hinders fast axonal transport of tau, possibly
because of stabilization of microtubules.
3.3. Increased motile particles of phosphomimic tau
We next examined the number of moving particles of exoge-
nously expressed tau in neurons (Fig. 4C). A minority of axons
expressing WTtau contained motile tau particles, resulting in the
detection of an average of 0.16 0.04 (mean standard error of the
mean; n ¼ 164) WTtau particles per axon (Fig. 4C). In contrast,
increased numbers of moving particles of E18tau (0.46  0.10 per
axon; n ¼ 106) and E27tau (0.78  0.16 per axon; n ¼ 100) were
detected, both of which were statistically signiﬁcantly different
from WTtau (Student t test, p < 0.05). These results demonstrate
that the frequency of motile particles of phosphomimic tau was
approximately 3e5-fold greater than that of WTtau (Fig. 4C).
Examination of individual axons harboring motile tau particles
showed that fewer motile particles of WTtau were present in the
same axon, compared with each of the tau phosphomimics
(Supplementary Videos 1e3). Thus, the probability of detecting 1
motile WTtau particle in an axon was 87%, and only 13% of axons
harbored more than 1 motile particle (Fig. 4D). In contrast,
approximately 50% of axons contained 1 moving particle of phos-


























































Fig. 4. Fast axonal transport of tau. (A) WTtau, E18tau, and E27tau exhibit a punctate morphology in axons in transfected neurons. Scale bar, 5 mm. (B) Kinetic parameters of motile
tau particles. Rate between pauses, time spent pausing, number of pauses, and longest distance traveled between pauses were calculated for each tau construct (WTtau, n ¼ 154;
E18tau, n ¼ 89; E27tau, n ¼ 81). (C) The number of motile particles per axon is shown for each tau construct. (D) The probability of ﬁnding 1 or more than 1 motile tau particle
moving in an individual axon was calculated from a randomized selection of movies (WTtau, n ¼12; E18tau, n ¼ 8; E27tau, n ¼ 7). Values shown are mean  standard error of the
mean. * p < 0.05, ** p <0.01, *** p < 0.001, Student t test, relative to WTtau.
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motile tau puncta, phosphorylation of tau signiﬁcantly increases its
probability of being transported in neurons and that tau axonal
transport is hindered by dephosphorylation. However, the likeli-
hood of movement of phosphomimic tau puncta did not appear to
inﬂuence their kinetic parameters. Furthermore, this mechanism
could help to explain in part the reduced overall rate of slow axonal
transport of tau observed after tau dephosphorylation in the
presence of lithium, that we observed previously with these
phosphomutant forms of tau (Cuchillo-Ibanez et al., 2008).
3.4. Pseudophosphorylation does not affect the ability of tau to bind
kinesin in neurons
We have previously shown that in vitro phosphorylation of
recombinant tau by GSK-3 increases the ability of tau to bind to theanterograde motor protein, kinesin-1 (Cuchillo-Ibanez et al., 2008).
To determine the effect of tau pseudophosphorylation on its
binding to kinesin-1 in neurons, primary cortical neurons were
transiently transfected with WTtau or the tau phosphomutants.
Cell lysates were incubated with GFP antibody linked to agarose
beads, to pull down exogenous tau, and bound proteins were pro-
bed on Western blots with antibodies to tau or kinesin heavy chain
(Fig. 5A). The relative amounts of kinesin and tau were quantiﬁed
and expressed relative to WTtau (Fig. 5B). We found that although
A18tau appeared to exhibit a trend toward reduced kinesin binding,
this difference was not statistically signiﬁcant (p ¼ 0.077) and the
phosphomimic tau mutants bound a similar amount of kinesin-1 as
WTtau.
Because kinesin and tau bindmicrotubules, it is possible that tau
could coprecipitate with kinesin through its binding to microtu-
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Input
Fig. 5. Tau pseudophosphorylation does not inﬂuence its binding to kinesin. (A)
WTtau, E18tau, E27tau, or A18tau were expressed in primary rat cortical neurons and
immunoprecipitated (IP) using an antibody to GFP. Total input and IP fractions were
analyzed on Western blots probed with antibodies to kinesin heavy chain (red) and tau
(green). (B) Kinesin/EGFPtau for each tau construct is expressed relative to WTtau.
Values shown are mean  standard error of the mean; n ¼ 3; Student t test, relative to
WTtau, showed no statistically signiﬁcant differences. (C) Western blot of GST pull-
down of WTtau and E27tau with GST-KLC1 and GST-KLC2, probed with tau antibody
(TP70). Abbreviations: EGFP, enhanced green ﬂuorescent protein; GFP, green ﬂuores-
cent protein; GST, glutathione-S-transferase; KLC, kinesin light chain.
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alone, or fused to kinesin light chain (KLC) 1 or KLC2, to pull down
recombinant WTtau or E27tau in the absence of microtubules.
Beads linked to GST-KLC1 or GST-KLC2, but not GST only, pulled
down substantial amounts of WTtau (Fig. 5C), however, very little
E27tau bound to KLC under the same conditions. The fact that this
result does not recapitulate the increased binding to kinesin
observed with GSK-3-phosphorylated tau suggests that the tau
phosphomimics might have some limitations as a model of direct
phosphorylation for all tau functions (Combs et al., 2011). For
example, E27tau harbors 5 glutamate serine subtitutions that are
not phosphorylated by GSK-3 and it is possible that 1 or more of
these mutated residues might negatively affect its association with
kinesin. Interestingly, however, our ﬁndings eliminate the possi-
bility that the increased number of motile particles of E27tau
observed in axons, relative to WTtau (Fig. 4C and D), is because of
enhanced kinesin binding by E27tau.
3.5. Exogenously expressed tau, but not endogenous tau, is
degraded by the autophagic system
Autophagy has been implicated as a potentially important
process in tau degradation, with some reports showing an inﬂuence
of tau phosphorylation on autophagic clearance (Kim et al., 2011;
Wang et al., 2009). To determine if some motile tau particles
correspond to autophagosomes, cortical primary neurons werecotransfected with EGFP-LC3 (a marker of autophagosomes) and
DsRed-E27tau. After 48-hour expression, we observed colocaliza-
tion of E27tau with LC3 (Supplementary Fig. 1). To further investi-
gate the effect of autophagy on tau degradation, we treated primary
rat cortical neurons expressing WTtau, or the tau phosphomutants,
with rapamycin (200 nM, 24 hours), to activate autophagy. In 7-DIV
neurons, rapamycin treatment did not reduce the amounts of either
endogenous or exogenous tau (Supplementary Fig. 2A). Further-
more, we found that rapamycin failed to activate autophagy
because no changewas detected in the ratio of the LC3 forms I and II
(Supplementary Fig. 2B). These results are in agreement with
a previous report in which rapamycin increased autophagic ﬂux of
endogenous tau in Neuro2A cells but not in primary cortical
neurons (Kruger et al., 2012).
We next treated rat cortical neurons expressing the different tau
constructs with 3-methyladenine (3-MA, 10 mM, 24 hours), which
blocks autophagy by targeting phosphoinositide 3-kinase (PI3K)
(Blommaart et al., 1997; Petiot et al., 2000). Neuronal lysates were
analyzed on Western blots probed with antibodies to tau, b-actin,
total ribosomal protein S6, phosphorylated T-S6 (P-S6), and LC3
(Fig. 6A). Phosphorylated S6 is a surrogate marker of mammalian
target of rapamycin activity, a key regulator of autophagy (Dann
et al., 2007). We found that 3-MA effectively inhibits autophagy,
conﬁrmed by suppression of PI3K-mediated phosphorylation of S6
(Fig. 6A). Accumulation of exogenous tau was measured by calcu-
lating the ratio of 3-MA-treated to untreated neurons after
normalizing to the amount of b-actin present (Fig. 6B). We found
that inhibiting autophagy increased the amount of all the exoge-
nously expressed tau forms, by 2e6-fold, without affecting
endogenous tau (Fig. 6B). E18tau increased approximately 3-fold
more than WTtau under conditions in which autophagy is inhibi-
ted by 3-MA (Fig. 6B; p < 0.05, 1-way analysis of variance). E27tau
and A18tau also accumulated with 3-MA treatment, but these
increases were similar to that of WTtau (Fig. 6B). These results
indicate that inhibition of autophagy reduces degradation of all of
the tau species examined, but that E18tau is affected more than the
other tau constructs. However, we did not ﬁnd any correlation
(Spearman rank) between the number of moving tau particles and
accumulation of tau because of inhibition of autophagy.
3.6. Proteasomal degradation of tau is modiﬁed by its
phosphorylation state
In addition to autophagy, tau can also be degraded by the UPS
and inhibition of the UPS results in increased amounts of tau in
SHSY-5Y cells (David et al., 2002) and rat brain (Liu et al., 2009). We
therefore examined the contribution of the UPS to tau degradation
in autophagy-deﬁcient MEFs lacking Atg5. To conﬁrm the lack of
autophagy in these cells, lysates of control Atg5þ/þ and autophagy-
deﬁcient Atg5-/- cells were probed on blots with an antibody to LC3.
As expected, LC3-I was present in both cell lines, but LC3-II was
undetectable in Atg5-/- MEFs because of the absence of autophagy
(Fig. 7A).
Atg5-/- autophagy-deﬁcient MEFs were transfected with
constructs expressing WTtau or the 3 tau phosphomutants.
Twenty-four hours after transfection, cells were treated with 100
mM cycloheximide, to block protein synthesis, and cells were har-
vested immediately, 12 hours, and 24 hours after treatment
(Fig. 7B). The absence of autophagy in MEFs did not lead to aggre-
gation of any of the tau species after 48-hour expression
(Supplementary Fig. 3). Atg5-/- MEFs expressing tau were lysed and
analyzed on Western blots using antibodies to tau and b-actin
(Fig. 7B). The amount of tau present at each time point was quan-
tiﬁed and expressed relative to the amount of tau present at 0 hours
(Fig. 7C). We found that, in comparisonwithWTtau, the amounts of
Fig. 7. Autophagy-deﬁcient MEFs exhibit differential degradation of tau phospho-
mutants. (A) Western blot of Atg5þ/þ and Atg5-/- MEFs probed with antibodies to
LC3 and b-actin. * Nonspeciﬁc band detected by the LC3 antibody. (B) Atg5-/- MEFs
were transfected with each tau construct. After 24 hours, cells were treated with 100
mM cycloheximide and harvested at 0, 12, and 24 hours. Cell lysates were analyzed on
Western blots probed with antibodies to tau (DAKO) and b-actin. (C) The amount of tau
remaining after cycloheximide treatment for 12 and 24 hours was calculated as the
percentage of tau present at 0 hours. Values shown are mean  standard error of the
mean; n ¼ 6; ** p < 0.01, *** p < 0.001, Student t test, relative to WTtau at 24 hours.
Abbreviations: EGFP, enhanced green ﬂuorescent protein; LC3, light chain 3; MEF,
mouse embryonic ﬁbroblasts.
Fig. 6. Inhibiting autophagy in cortical neurons results in differential degradation of
tau phospho-mutants. Neurons were transfected with each tau construct and treated
with 10 mM 3MA. (A) Cell lysates were analyzed on Western blots probed with anti-
bodies to tau, b-actin, total and phosphorylated (P) ribosomal S6 protein, and LC3.
* Nonspeciﬁc band detected by the LC3 antibody. (B) EGFPtau accumulation expressed
as a ratio of 3MA-treated and untreated neurons, normalized to b-actin. Values shown
are mean  SEM; n ¼ 5e6; 1-way analysis of variance. (C) Endogenous tau accumu-
lation expressed as a ratio of 3MA-treated and untreated neurons, normalized to b-
actin. Values shown are mean  SEM; n ¼ 6. Abbreviations: EGFP, enhanced green
ﬂuorescent protein; LC3, light chain 3; SEM, standard error of the mean.
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phosphomimics exhibited reduced rates of degradation by the UPS,
comparedwithWTtau (Student t test, p< 0.05). The estimated half-
lives for WTtau, A18tau, E18tau, and E27tau in MEFs were
approximately 16, 18, 21, and >24 hours, respectively. These results
are in line with those obtained from 3-MA-treated neurons
expressing E18tau (Fig. 6), showing that E18tau is more likely than
WTtau to be degraded by the autophagic route. However, E27tau
did not accumulate in 3-MA-treated neurons compared with
WTtau, and exhibited a reduced degradation rate by the UPS in
MEFs. A possible explanation for this difference between the 2 tau
phosphomimics could be that the 9 additional glutamate substi-
tutions in E27tau might cause the protein to adopt a conformation
which affects its recognition by the degradation machinery.3.7. Proteasomal degradation of tau is minimal in cortical neurons
To test if the proteasome system has a role in tau degradation in
neurons, we used the same approach of inhibiting protein synthesis
with cycloheximide to measure the rate of tau degradation in
primary neurons. Cycloheximide causes an early suppression of
autophagy because this process requires the involvement of
multiple short-lived proteins that are essential for early autopha-
gosome formation (Lawrence and Brown, 1993). Thus, in neurons
treated with cycloheximide, the UPS, but not autophagy, remains
effective, and hence the contribution of the proteasome to tau
degradation can be measured.
Rat primary cortical neurons exogenously expressing each of the
4 tau species, were treated with 100 mM cycloheximide 48 hours
after transfection and cells were harvested immediately, and 12 and
24 hours after treatment (Fig. 8A). Neuronal lysates were analyzed
on Western blots using antibodies to tau and b-actin, and the
amount of tau remaining at 12 and 24 hours was calculated as the
percentage of EGFP-tau present at 0 hours (Fig. 8A). Under condi-
tions of autophagy inhibition and an active UPS, endogenous and
exogenous tau exhibited very low rates of degradation in neurons
Fig. 8. Lack of tau degradation by the proteasome in neurons. (A) Primary rat cortical
neurons were transfected with each tau construct. After 48 hours, neurons were
treated with 100 mM cycloheximide and harvested at 0, 12, and 24 hours. Neuronal
lysates were analyzed on Western blots probed with antibodies to tau (DAKO) and b-
actin. (B) The amount of EGFPtau remaining after cycloheximide treatment for 12 and
24 hours was calculated as the percentage of tau present at 0 hours. Values shown are
mean  standard error of the mean; n ¼ 6. Abbreviations: DIV, days in vitro; EGFP,
enhanced green ﬂuorescent protein; Endog, endogenous.
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remaining in neurons was similar at 0, 12, and 24 hours after
application of cycloheximide (Fig. 8B). The half-lives of all of the
exogenously expressed tau species in neurons exceeded 24 hours
and only minimal tau degradation was observed at this time point.
These results demonstrate that the UPS has a very limited capability
to degrade endogenous tau in cultured cortical neurons and hence
tau turnover is very low under these conditions.
4. Discussion
Here we have investigated the effect of tau phosphorylation on
its rate of axonal transport and degradation. The tau phosphomi-
mics, E18tau, and E27tau (Goedert et al., 1989; Smith et al., 2000),
harbor glutamate substitutions of serine and threonine residues
that correspond to many of those targeted by GSK-3, a candidate
kinase for tau phosphorylation (Hanger et al., 2007). Thus, 16 sites
in E18tau and 22 sites mutated in E27tau are reported to be targets
of GSK-3 phosphorylated tau, suggesting that these constructs
might represent reasonable mimics of phosphorylated tau when
expressed in cells.
Ectopic expression of tau in a variety of cell types results in the
appearance of characteristic bundles of microtubules, presumed to
result from increased tubulin stabilization (Kanai et al., 1989;
Langkopf et al., 1995; Lee and Rook, 1992; Scott et al., 1992;
Stoothoff et al., 2008; Takemura et al., 1992). Therefore, we ﬁrst
established the microtubule bundling properties of the tau phos-
phomutants in CHO cells. Though untransfected cells exhibit an
ordered microtubular array, WTtau induces the formation of
bundles of microtubules that frequently appeared as a thick ringencircling the inner periphery of the cell. E18tau and E27tau
expression did not alter either the size or morphology of CHO cells,
and microtubule bundles were rarely observed, even in cells highly
expressing the phosphomimic tau constructs. In contrast, even low
expression of A18tau caused microtubules to bundle very effec-
tively. E18tau and E27tau bind less well to microtubules compared
withWTtau and, conversely, A18tau showed increasedmicrotubule
binding. These ﬁndings are in good agreement with our observa-
tions of the effects of these tau variants on microtubule bundling,
and also with previous reports of reduced microtubule binding by
phosphorylated tau (Bramblett et al., 1993; Busciglio et al., 1995;
Wagner et al., 1996). Our data support the view that a greater
proportion of highly phosphorylated tau might be detached from
microtubules in neurons compared with tau phosphorylated to
a low stoichiometry. Lack of binding of phosphorylated tau to
microtubules would effectively increase cytoplasmic tau, which
could result in the formation of intracellular tau aggregates in the
tauopathies.
We examined the axonal transport kinetics of tau because
regulation of microtubule binding and tubulin stabilization are
important for the axonal transport of multiple cargoes (Ebneth
et al., 1998; Mandelkow et al., 2003). Interestingly, compared
with WTtau, we observed signiﬁcantly more motile particles of
phosphomimic tau in individual axons, and this correlated with the
degree of tau phosphorylation (p < 0.05). However, phosphomimic
tau particles are indistinguishable fromWTtau with respect to their
velocity and the number and duration of pauses. This ﬁnding
suggests that, when the molecular motor complex binds to tau, its
phosphorylation state does not inﬂuence transport kinetics. We did
not detect any movement of the nonphosphorylatable A18tau,
possibly because of its increased microtubule binding. Notably, we
found that coexpression of WTtau and E27tau in neurons resulted
in their codistribution, although a proportion of E27tau puncta did
not overlap with the generally more diffuse axonal WTtau. A
plausible explanation for this ﬁnding is that phosphorylated tau has
a reduced ability to bind to microtubules, which could result in
accumulation of E27tau.
The increased number of motile phosphomimic tau particles
observed in the axonal transport analysis led us to investigate
changes in tau degradation that could explain the increase of
pseudophosphorylated tau protein. The autophagic and protea-
some systems have been linked to tau degradation and we decided
to study the contribution of both pathways to tau accumulation.
Autophagosome dynamics in primary neurons has been described
by Maday et al. (2012), who found that autophagosome biogenesis
occurs distally in the axon. Autophagosomes switch from an initial
bidirectional movement to unidirectional movement toward the
cell soma driven by dynein at a mean speed of 0.45 mm/s. Thus, the
puncta comprised of solely E27tau in our coexpression experiment
could represent autophagosomes undergoing retrograde transport,
a view supported by our ﬁnding of colocalization of E27tau with the
autophagic marker, LC3.
The role of autophagy in neurodegeneration is controversial,
with some reports concluding that inhibiting autophagy is neuro-
protective (Sadasivan et al., 2010; Wang et al., 2011), and other
studies showing that activating autophagy, using rapamycin,
trehalose, or methylene blue, reduces aggregated proteins and
improves neuronal survival (Berger et al., 2006; Congdon et al.,
2012; Renna et al., 2010; Sarkar and Rubinsztein, 2008). Interest-
ingly, a recent study ofmutant P301S tau transgenicmice has shown
that enhancing autophagy reduces tau aggregates, decreases
insoluble tau, and improves neuronal survival (Schaeffer et al.,
2012). In agreement with a previous report, we were unable to
detect an effect of rapamycin in primary cortical neurons (Kruger
et al., 2012) and endogenous tau did not accumulate in neurons
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et al., 2009, 2010). These results are in agreement with a previous
study examining tau degradation in rat brain (Zhang et al., 2009).
Taken together, these results suggest that autophagy is unlikely to
be amajor contributor to degradation of endogenous tau in neurons.
In contrast to the lack of effect of autophagic inhibition on
endogenous tau, exposure of neurons to 3-MA resulted in the
accumulation of exogenously expressed wild type and phospho-
mutant tau. 3-MA induced the accumulation of all forms of exog-
enously expressed tau, with E18tau increasing 3-fold relative to
WTtau. This ﬁnding implies that there might be conformational
differences between the 2 tau phosphomimics, which could result
in differential recognition of phosphorylated forms of tau as
a substrate for degradation. Our ﬁndings support and extend
reports of the effects of 3-MA onwild type and phosphomutant tau
in cells (Kim et al., 2011; Wang et al., 2009) and suggest that
elevated phosphorylation could enhance tau degradation by the
autophagic pathway.
To determine the effect of the proteasome on tau in neurons, in
conditions in which autophagy is inhibited, we treated cultured
neurons with cycloheximide to prevent synthesis of proteins
involved in early autophagosome formation and hence measure
primarily proteasomal degradation. In conditions when autophagy
is inhibited, tau degradationwasminimal after 24hours, in linewith
its reported half-life of approximately 60 hours in HT22 cells
(Poppek et al., 2006). All forms of exogenous tau were degraded at
a similar rate to endogenous tau, with exogenously expressed
phosphomutant tau appearing to be degraded slightly slower than
WTtau, although this difference was not signiﬁcant. Though our
results are suggestive that increased phosphorylation might reduce
the rate of tau degradation, this could not be determined conclu-
sively because of the slowoverall rate of tau degradation in neurons.
Interestingly, the effect of autophagy inhibition using 3-MA is
not recapitulated in neurons expressing the phosphomutants and
treated with cycloheximide, which also inhibits autophagy. A
possible explanation for this is that cycloheximide inhibition of
autophagy might be secondary to blockage of protein synthesis
(Lawrence and Brown, 1993). Treatment of neurons with 3-MA
results in the speciﬁc blocking of autophagy through PI3K inhibi-
tion. Another possibility is the potential cross-talk between auto-
phagy and the UPS in neurons in which inhibition of autophagy
could also decrease the efﬁciency of the UPS (Korolchuk et al.,
2009). Blocking autophagy has been shown to lead to an increase
in proteasomal substrates, which can be explained by the accu-
mulation of p62, resulting in delayed delivery of ubiquinated
proteins to the proteasome (Korolchuk et al., 2009).
The effect of proteasome inhibition on tau in cultured embryonic
neurons is also somewhat controversial. Inhibiting the proteasome
has been reported not to affect the amount of tau in neuronal cells
(Brown et al., 2005). In contrast, when tau is exogenously expressed
in HT22 cells, phosphorylation inhibits its degradation by the pro-
teasome (Poppek et al., 2006). Proteasome inhibition in vivo also
increases the amount of tau in rat brain, suggesting that this
mechanismmight have a role in regulating turnover of endogenous
tau (Liu et al., 2009). One possible explanation for these contradic-
toryﬁndings could be thewidespread use ofMG132 as a proteasome
inhibitor. MG132 has pleiotropic effects that include: (1) modifying
cytomegalovirus promoter expression, which could affect exoge-
nous tau expression in some studies (Biasini et al., 2004); (2) acti-
vation of calpain, which could result in increased tau cleavage
(Hamano et al., 2009); and (3) induction of autophagy (Du et al.,
2009; Klappan et al., 2012; Zheng et al., 2011). This highlights the
difﬁculty of studying the effect of a speciﬁc proteolytic system in
cells because cross-talk and potential compensation between
autophagyand the proteasomehave been reported (Korolchuk et al.,2010; Zheng et al., 2009). To eliminate these confounding factors,
we examined tau degradation in autophagy-deﬁcient MEFs, which
lackAtg5, a gene involved in autophagosome formation (Kuma et al.,
2004). Atg5-/- MEFs are dependent for proteolysis on cellular
mechanisms other than autophagy, and proteins are therefore
eliminated by the proteasome and/or by calpain-mediated degra-
dation. Even when highly expressed, WTtau, E18tau, E27tau, and
A18tau did not form aggregates in Atg5-/- MEFs, suggesting that
inhibition of autophagy might not have a marked effect on tau
accumulation in these cells. However, there was a signiﬁcant
reduction in the rate of degradation of the tau phosphomutants
compared with WTtau, indicating that increased phosphorylation
might reduce tau degradation by the UPS and/or calpain, possibly
directing tau toward an autophagic route.
Extrapolation of these results to neurons undergoing neuro-
degeneration, in which tau phosphorylation plays a key role,
suggests a mechanism whereby highly phosphorylated tau could
result in abnormal accumulation of cytoplasmic tau and a cascade
of secondary events that might contribute to neurotoxicity and cell
death. For example, increased steady-state amounts of phosphor-
ylated cytoplasmic tau could overload kinesin-based molecular
motor transport mechanisms, thereby blocking or reducing the
movement of other cargoes, including mitochondria and vesicles.
Thus, it is plausible that increased axonal transport could contribute
to the mislocalization and accumulation of tau, and thereby
participate in the spreading of tau pathology in neurodegenerative
disease. Secondly, increased phosphorylation could lead to the
removal of tau from the plasma membrane, and potentially to
disruption of intracellular signaling pathways (Brandt et al., 1995;
Pooler and Hanger, 2010; Pooler et al., 2012). Finally, binding of tau
to the plasmamembrane and to microtubules could be essential for
autophagic ﬂux because the plasma membrane is a major source of
autophagosomal components (Cuervo, 2010; Ravikumar et al.,
2010), and autophagy is dependent on microtubule integrity
(Aplin et al., 1992; Webb et al., 2004).
We conclude that in autophagy-deﬁcient mouse embryonic
ﬁbroblasts, but not in neurons, proteasomal degradation of phos-
phomutant tau is reduced compared with wild type tau. Autophagic
and proteasomal pathways are involved in tau degradation, with
autophagy appearing to be the primary route for clearing phosphor-
ylated tau in neurons. Enhancing the autophagic pathway might
have potential as a novel therapeutic approach for the removal of
damaging, highly phosphorylated and aggregated proteins in Alz-
heimer’s disease and other neurodegenerative disorders.
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